Show simple item record

dc.contributor.authorMcAleese, JJen_US
dc.contributor.authorStenning, SPen_US
dc.contributor.authorAshley, Sen_US
dc.contributor.authorTraish, Den_US
dc.contributor.authorHines, Fen_US
dc.contributor.authorSardell, Sen_US
dc.contributor.authorGuerrero, Den_US
dc.contributor.authorBrada, Men_US
dc.date.accessioned2018-09-17T08:19:36Z
dc.date.issued2003en_US
dc.identifier2en_US
dc.identifier.citationRadiotherapy and Oncology, 2003, 67 pp. 177 - 182en_US
dc.identifier.issn0167-8140en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2684
dc.identifier.doi10.1016/S0167-8140(03)00077-Xen_US
dc.description.abstractPurpose: To assess the survival benefit of palliative hypofractionated radiotherapy in patients with poor prognosis high grade glioma by a matched comparison to conventionally treated controls. Method: Ninety-two elderly and/or disabled patients with high grade glioma with poor prognostic features received palliative partial brain radiotherapy to a dose of 30Gy in six fractions over 2 weeks. Patients were matched for WHO histological grade, performance status and age from a cohort of patients treated with conventionally fractionated radiotherapy to a dose of 60Gy in 30 fractions in an Medical Research Council (MRC) BR05 trial. Results: Patients treated with hypofractionated radiotherapy had a median survival of 5 months with a 1-year survival rate of 12% from diagnosis. The median survival of case-matched controls was estimated to be 2.5–4.5 months longer. Following hypofractionated radiotherapy, Barthel score was improved or remained stable in 68% of patients. Conclusion: Hypofractionated partial brain radiotherapy is a well-tolerated regimen with palliative benefit. Comparison with matched controls suggests lesser survival benefit than would be obtained with radical radiotherapy. However, this is compensated by lower intensity and duration of irradiation induced side effects. It is postulated that there may not be a significant difference in good quality survival or ‘quality adjusted survival’ between the two regimens and this requires testing in prospective trials.en_US
dc.format.extent177 - 182en_US
dc.titleHypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controlsen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/S0167-8140(03)00077-Xen_US
rioxxterms.licenseref.startdate2003en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfRadiotherapy and Oncologyen_US
pubs.noteskeywords: Radiotherapy, High grade glioma, Palliationen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.volume67en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Brada)en_US
dc.contributor.icrauthorBrada, Michaelen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record